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Immunosuppressive medicines are characterized by specific pharmacokinetic profile 
which requires therapy monitoring by means of measuring their blood concentrations. 
Therapy monitoring, by means of determining blood concentration of the medicine, 
enables application of an optimal individual immunosuppressive therapy. Due to its 
variable pharmacokinetics, and small therapeutic index and potential interaction with 
numerous other medicines, the post-operative monitoring of immunosuppressive 
medicines is an essential element of therapy protocol for renal transplantation patients. 
Therapy monitoring represents an efficient way to reduce adverse effects of 
immunosuppressive medicines and to prevent transplantation rejection by means of 
adapting the doses in renal transplantation patients. Determining the concentration of 
immunosuppressive medicines is of special importance in the modified dosing for patients 
with renal insufficiency. Pharmacokinetic analysis is important for proper interpretation of 
immunosuppressive medicines' blood concentrations. The interpretation of the received 
results must be multidisciplinary, considering that there are numerous factors of variability 
of patients and immunosuppressive medicines. Acta Medica Medianae 2009;48(2):22-27. 
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Introduction 
 
Immunosuppressive medicines prevent organ 
rejection by developing immunotolerance to specific 
antigens with preservation of immunological ability 
of the organism as a whole (1). 
Out of immunosuppressive medicines we most 
commonly use: cyclosporine (CsA), sirolimus, tacroli-
mus (Tc), azathioprine, mycophenolate mofetil 
(MFM) and corticosteroids (KS). As of recently, 
immunosuppressive therapy also includes mono-
clonal antibodies, biomolecules (for example basilixi-
mab,daclizumab). 
Immunosuppressive medicines are characte-
rized by a specific pharmacokinetic profile which 
requires therapeutic monitoring (Therapeutic 
Drug Monitoring- TDM), by means of recording 
blood level concentrations. Reasons for application 
of TDM immunosuppressive medicines are as 
follows: 
• Small therapeutic index (TI). 
• Correlation of concentrations and therape-
utic or toxic effects.  
• Metabolism through cytochrome P450. 
• Great individual differences. 
•  Risk for developing interactions with 
other medicines. 
• Monitoring patient adherence (2). 
Tc and CsA plasma concentrations above 
upper limits of therapeutic index are associated 
with the increased incidence of adverse reactions 
(nephrotoxicity, hepatotoxicity), while their lower 
concentrations increase the risk for organ rejection. 
Therapeutic monitoring of immunosuppressive 
medicines is done by determining their levels in 
patient’s blood. When TDM is applied in order to 
adjust the dosage, medication concentration 
must be in a state of dynamic balance, that is, 
there must elapse 5 half-life times for medicine 
elimination. Deviation of this rule is only in the 
case of suspicion that there is toxicity. When the 
state of dynamic balance is achieved, it is 
important to timely take blood samples, have a 
valid analytical procedure and interpret the 
results accurately (2-4). 
 
Characteristics of therapeutic monitoring 
for immunosuppressive medicines 
 
In general, TDM by determining plasma 
concentration of the drug, enables the application 
of optimal individual immunosuppressive therapy. 
When monitoring immunosuppressive medicines 
and their metabolites, plasma concentrations 
must be precisely planned and accompanied by Acta Medica Medianae 2009,Vol.48                           Significance of therapy monitoring of immunosuppressive... 
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appropriate sampling of biological material and 
valid analytical procedure. The interpretation of 
the received results is of special importance and 
must be multidisciplinary considered that there 
are numerous factors of variability of patients 
and immunosuppressive medicines (Table 1) (4-6). 
 
Table 1. Variability factors influencing the concentration 
of immunosuppressive medicines 
 
Patient factor  Medicine factor 
Adherence Medicine  quality 
Individual capacity, absorption 
and distribution characteristics  
Manner and time of 
application 
Individual capacity, metabolism 
characteristics and  medicine 
excretion 
Treatment type 
Body mass index (BMI), body 
surface 
Treatment mistakes 
Significant co morbid states  Time of sampling 
Other medicines 
Interferences in 
analytical procedure 
Physiological/pathophysiological 
factors 
 Selectivity of the 
chosen method 
Factors of environment 
Efficiency of the 
chosen method 
 
Pharmacokinetic analysis is important for 
correct interpretation of the received immuno-
suppressive medicines plasma concentrations. 
Concentrations of immunosuppressive medicines 
lower or higher than expected can be the result 
of inadequate cooperation between the patient 
and his physician (adherence), wrong choice, 
medicine dosage of the time of biological material 
sampling (5,7).  
Concentrations of the medicine lower than 
expected are most often the result of a poor bioa-
vailability of the medicine, its elimination faster 
than expected, increased distribution volume and 
inability to achieve balance (1,2,5). 
Alternative immunosuppressive medicine 
monitoring is a much simpler method that includes 
following the function and reaction of organ 
rejection in patients on immunosuppressive therapy 
based on appropriate biochemical parameters 
(urea, creatinine, creatinine clearance) and 
radiological examinations (echo, Doppler).  
Immunosuppressive protocols are dominated 
by calcineurine inhibitors (cyclosporine, tacrolimus ) 
which are used in combination with other immuno-
suppressive medicines (mycophenolate mofetil, 
sirolimus, corticosteroids, basiliximab). 
Due to its variable pharmacokinetics and a 
small therapeutic index, post-transplant monito-
ring of immunosuppressive medicines is an 
essential part of patient therapeutic monitoring, 
which enables optimal treatment with significant 
reduction of risk for nephrotoxicity, heaptotoxi-
city and transplant rejection (8,9). New formula-
tions of immunosuppressive medicines with spe-
cific pharmacokinetics require constant monitoring 
of medication blood levels. Therapy monitoring 
enables titration of the dosage depending on 
patients individual characteristics and considerations 
for their inter and intra- individual differences (8-10). 
 
Specificities of therapy monitoring of 
immunosuppressive medicines  
 
Calcineurine inhibitors are the most commonly 
used immunosuppressive medicines in the medical 
practice. Their similar pharmacokinetic features 
spring from the same mechanism of action and 
similar metabolism, dependant on the activity of 
CYP 3A4 enzyme and P-glycoprotein (Figure 1). 
 
 
 
 
Figure1. Mechanism of action for calcineurin immunosuppressive medicines 
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Cyclosporine (CsA) 
 
Cyclosporine is one of the first immunosu-
ppressive medicines to be applied. Its molecule 
represents neutral lipophile undecapeptide which 
within cells easily makes complex with cyclophilin, 
cell protein, inhibiting the activity of calcineurin 
phosphatase. As a consequence there occurs 
dephosphorization and nuclear translocation in T-
cells, which thereby become inhibited. The efficiency 
of cyclosporine depends on specific reversible 
lymphocyte inhibition in G0 and G1-phase of cell 
cycle. T-lymphocytes are inhibited with greater 
specificity. T-helper cells are the main target, 
although T-suppressor cells can also be affected. 
Cyclosporine also inhibits creation and release of 
lymphokines including interleukin-2. CsA does 
not affect phagocyte function and does not cause 
bone marrow suppression (5,11).  
CsA formulation determines the degree of 
its absorption from oral medicines and consequently 
its bioavailability. Cyclosporine is distributed 
mostly outside blood volume, penetrating deeply 
into tissues and bodily fluids, including liver, 
pancreas, and lungs.  Distribution volume during 
the state of balance, during intravenous dosing is 
3-5 L/kg (4-6) in transplant recipients (children 
younger that 10 have higher clearance values). 
Distribution of medicine in blood depends on its 
concentration. Approximately, 33-47% of the 
medicine is in plasma, 4-9% in lymphocytes, 5-
12% in granulocytes and 41-58% in erythrocytes. 
In higher concentrations of CsA there is a satu-
ration of its binding to leukocytes and erythrocytes. 
In plasma, approximately 90% of the medicine is 
bound to proteins, primarily lipoproteins. 
Cyclosporine goes through placenta and is 
excreted with human milk. Plasma concentrations 
in the state of balance are 75-150 µg/l (4,6).  
CsA metabolism is performed through 
system 3A oxigense CYP 450 in the liver, and in a 
smaller degree in the gastrointestinal tract and 
the kidneys. After oral application, it is characte-
rized by the phenomenon of the first pass. All 
medicines whose metabolism is conducted by the 
same enzyme system can affect CsA metabolism. 
Around 25 metabolites have been identified from 
human bile, feces, blood and urine. Main metabo-
lites (M1, M9, and M4N) are created as products 
of oxidation at position 1-beta, 9-gama, and 4-N-
demethilation. Secondary metabolite M19 and 
cyclic forms of main metabolites M1c and M1c9 
are responsible for reduction in renal function 
and nephrotoxicity. Elimination of cyclosporine is 
performed mainly through bile, while only 6% of 
the dose (basic medicine and metabolites) is 
excreted by urine.  
 
Table 2. Clinically significant interactions of calcineurine inhibitors (CNI) 
 
Medicine interacting with CNI  Action mechanism  Interaction effect 
trimetoprim+sulfametoxazole Unclear  mechanism  ↓  conc..CNI 
ditiazem  Competition in metabolism  ↑   conc.CNI 
phenytoin  Liver enzyme induction  ↓  conc.CNI 
phenobarbitone  Liver enzyme induction  ↓  conc.CNI 
rifampicin  Liver enzyme induction  ↓  conc.CNI 
isoniazid  Liver enzyme induction  ↓  conc.CNI 
sirolimus addition  ↑ immunosupppresion 
ketoconazole Liver  enzyme induction  ↑  conc. CNI 
erythromycin  Competition in metabolism  ↑  conc. CNI 
corticosteroids Liver enzyme induction  ↑ conc. CNI 
Hormones of synthetic origins  Competition in metabolism  ↑  conc CNI 
amphotericin B  addition  ↑nephrotoxicity 
Aminoglycoside antibiotics  addition  ↑  nephrotoxicity 
alopurinol Metabolism  inhibition  ↑  conc. CNI 
diclofenac  Increased absorption of dikl.  ↑ conc diklofenak 
methotrexate  Increased absorption  metot.  ↑ conc.metotreksat 
Hyperici herba  Liver enzyme induction  ↓  conc. CNI 
Echinaceaae herba  immunostimulation  Contraindicated application 
naringenin 
Increased absorption of the 
medicine  ↑  conc.of medicine 
Oral contaceptives  Metabolism modification 
Extended half-time of 
elimination 
nifedipine Metabolism  inhibition  ↑  conc. CNI 
bromocriptine Metabolism inhibition  ↑  conc. CNI 
Potent inhibitors CYP 3A4  Metabolism inhibition  ↑ conc. CNI 
Potent  inductors CYP 3A4  Metabolism induction  ↓ conc. CNI Acta Medica Medianae 2009,Vol.48                           Significance of therapy monitoring of immunosuppressive... 
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Adverse effects for CsA include renal insu-
ficiency, hyperkalemia, hypertension, gingive 
hypertension, gastrointestinal and neurological 
toxicity (1,12). Cyclosporine is substrate for 
CYP3A4 and moderate inhibitor of its activity. It 
also occurs as a weak inhibitor of CYP2C8/9. 
These characteristics of CsA indicate a high 
potential for interactions with other medicines. 
Many interactions with antibiotics have been 
registered (Table 2). Nepphrotoxicity is enhanced 
in simultaneous application of aminoglycosides, 
vancomycin and trimetoprim- sulphametoxazol (13). 
Macrolide antibiotics (clarithromycin, erythromycin) 
as well as norfloxacin increase CsA by inhibiting 
its metabolism. Rifampicin and ciprofloxacin can 
reduce immunosuppressive action of CsA by 
inducing its metabolism (12,13). Imipenem should 
be avoided due to its neurotoxicity. Insignificant 
pharmacokinetic interactions with aspirin, piroxicam, 
ketoprofen and indomethacin were observed. CsA 
increase diclofenac concentration (3,5,10). 
Grapefruit juice increases absorption and 
bioavailability of CsA, and should be avoided 
during the therapy. 
In recent times, more importance is given 
to monitoring CsA plasma concentrations two 
hours after oral administratio (C2), because of 
better correlation with therapeutic effect of the 
medicine (11,12). 
 
Tacrolimus (Tcr) 
 
Tacrolimus (Tcr) is macrocyclic lactone. Its 
inhibitory activity is more selective compared to 
CsA. Tcr binds to the proteins in the cell which 
are included into calcineurine and in this way 
inhibits its activity. 
Tacrolimus is characterized by poor absorption 
from oral medicines and its bioavailability is only 
20%. Elimination half-life is variable and is 3-
40h. Tcr metabolism is performed in the liver 
through actions of oxidases, most of all CYP 3A4, 
when a large number of metabolites is produced, 
out of which 5 have immunological activity. 
Excretion is mostly done through the bile. Tcr 
potential for interactions is high. In vitro studies 
have shown that medicines which inhibit CYP 3A4 
have an influence on Tcr plasma concentrations 
inhibiting its metabolism (10,11). Such medicines 
are: bromocriptine, cortisone, dapsone, ergotamine, 
etinilestradiol, gestodene, itraconazole, josamycine, 
lidocaine, mephenytoin, miconazole, midazolam, 
nicardipine, nifedipine, nilvadipine, norethisterone, 
hinidin, tamoxifen, verapamil. It is also important 
to mention kaptopril, chloramphenicol, cimetidine, 
clarithromycin, cyclosporine, danazol, fluconazole, 
ketoconazole, metoclopramide, omeprazole, predni-
solone and sulindac. Naringenin, ingredient of 
grapefruit juice, known as inhibitor of most of all 
intestinal CYP 3A4, influence concentration of Tcr 
by changing bioavailability of the medicine. 
Enzyme inductors cytochrome 3A generally 
reduce Tcr concentration. In the same way act 
barbiturates, rifampicin, phenytoin, carbamazepine, 
metamizole and isoniazid. Tcr inhibits CYP 3A4 
activity, which can influence the efficiency of oral 
contraceptives or prolong half-time of CsA elimination, 
if they are applied at the same time (4,10,11,15). 
 
Sirolimus (Syr) 
 
Sirolimus is macrocyclic lactone structurally 
similar to tacrolimus. Similarly as other immuno-
suppressive medicines Syr requires TDM due to 
great variability in pharmacokinetics, most of all, 
distribution volume, clearance and maximal plasma 
concentration (16). Monotherapy by sirolimus 
shows therapeutic effects at concentrations 16,9-
29,6 µg/l. When the protocol also includes CsA, 
therapeutic concentration range is somewhat lower 
and is at 5-15 µg/l. Syr metabolism is performed 
through enzyme CYP 3A4, with pronounced pre-
systemic metabolism of the medicine because of 
action of intestinal CYP 3A4. Syr metabolism also 
includes P-glycoproteine which also causes the 
variability of pharmacokinetics and high potential 
for interaction with other medicines which are 
metabolized through the same enzymes. Great 
number of papers deals with interaction between 
CsA and Syr. It is established that sirolimus does 
not have significant influence on the level of 
reabsorbed CsA, expressed through AUC (area 
under  the curve), while the influence of CsA on 
AUC of sirolimus is much greater (4,7,15). These 
data favor monitoring as a way for rational 
therapy with sirolimus (Table 2).   
 
Mycophenolate Mofetil (MMF) 
 
Mycophenolate is a precursor and chemically 
represents estar of mycophenolic acid. MMF is 
applied perorally, its bioavailability is around 
94% and is susceptible to variability. Active form 
of the medicine is quickly released in the organism 
(MPA), which by means of glucuronidation, most 
of all in liver, is transformed into non-active β- 
glucuronide and eliminated by means of urine. 
Apart from this inactive form, it is considered 
that there is one active metabolite MPA but this is 
not yet proven. In the active form, the medicine 
inhibits the production of guanine nucleotides 
which hinder the immunological reaction of the 
organism. In practice, MMF is used in combination 
with other immunosuppressives (15). Therapeutic 
concentrations in combination with CsA are 14,1-
34,9 µg/l, and in combination with Tcr 11,9-25,4 
µg/l. Interactions with other medicines are possible 
(Table 3). Antacids reduce its absorption. Simu-
ltaneous application of acyclovir and MMF leads 
to increased concentrations of both medicines 
probably due to competition on the level of renal 
tubules in glucuronidation reaction. Because of 
possible change in plasma concentrations and the 
consequent activity of the medicine it is necessary 
to take care in all medicines susceptible to entero-
hepatic circulation. Simultaneous application of 
MMF and azathioprim can lead to bone marrow 
depression. Corticosteroids and CsA reduce MPA 
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Table 3. Clinically significant interactions of MMF with 
other medicines 
 
Medicine 
interacting 
with MMF  
mechanism  effect 
azathioprine sinergism 
Bone marrow 
depression 
aciklovir competition 
↑ conc. of both 
medicines 
cyclosporine - 
↓ conc.MPA za 
30-40% 
antacides 
Reduced 
absorption 
↓conc. MPA 
corticosteroids Enzyme  expression ↓conc. MPA 
 
Basiliximab (Bas) 
 
Basiliximab is a representative of a new gene-
ration of immunosuppressive medicines from the 
group of biomolecules. Basiliximab represents 
himar monoclonal antibody Ig1k, produced by 
recombinant DNA technology. As antagonist of 
IL2 receptor with high affinity for binding, it 
blocks function of IL2R that is cell immune response 
and the rejection of the transplanted organ. In 
basiliximaba pharmacokinetics there is a dosage 
depandance of the parameters (Cmax, AUC), but 
the area in which the medicine is distributed has 
not been defined yet. Distribution volume and 
clearance point to interindividual variability. Sex, 
age and race do not have influence on half-time of 
elimination which is 7,2±3,2 days. Simultaneous 
use of mycophenolate mofetil and azathioprim can 
significantly reduce the clearance of the medicine 
(do 22%) (17,18). 
 
Conclusion  
 
Therapy monitoring represents an efficient 
way to reduce adverse effects of immunosuppre-
ssive medicines and to prevent transplantation 
rejection, by means of adapting the doses in renal 
transplantation patients. Determining concentra-
tions of immunosuppressive medicines is of especial 
importance in modified dosing in patients with renal 
insufficiency. Therapeutic moni-toring of plasma 
concentrations of immunosu-ppressive medicines 
and metabolites in biological fluids requires correct 
sampling of the biological material, accurate 
measurements of concentra-tions and detailed 
knowledge of pharmacokinetic principles, parameters 
as well as adequate interpretation of the obtained 
results. The choice and correct application of 
analytical procedure are most of all dependent on 
technical and material capacities of clinics and 
laboratories. 
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ZNAČAJ TERAPIJSKOG PRAĆENJA IMUNOSUPRESIVNIH LEKOVA KOD 
BOLESNIKA SA PRESAĐENIM BUBREGOM 
 
Radmila Veličković-Radovanović, Aleksandra Catić-Đorđević, Goran Paunović i Vidojko Đorđević 
 
Imunosupresivne lekove karakteriše specifičan farmakokinetski profil koji nameće 
potrebu za terapijskim praćenjem njihove koncentracije u plazmi. Terapijsko praćenje, 
određivanjem koncentracije leka u plazmi omogućava sprovođenje optimalne individualne 
imunosupresivne terapije. Zbog svoje varijabilne farmakokinetike, malog terapijskog 
indeksa i potencijalnih interakcija sa brojnim lekovima, praćenje imunosupresivnih lekova 
je esencijalni segment terapijskog protokola kod bolesnika sa presađenim bubregom. 
Terapijsko praćenje predstavlja efikasan način za smanjenje neželjenih efekata 
imunosupresivnih lekova i sprečavanje odbacivanja organa, prilagođavanjem režima 
doziranja kod bolesnika sa presađenim bubregom. Određivanje koncentracije 
imunosupresivnih lekova je od naročitog interesa u modifikovanom doziranju kod bolesnika 
sa bubrežnom insuficijencijom. Farmakokinetička analiza je značajna u pravilnoj 
interpretaciji dobijenih koncentracija imunosupresivnih lekova u plazmi. Tumačenje 
dobijenih rezultata mora biti multidisciplinarno, s obzirom na postojanje brojnih faktora 
varijabilnosti bolesnika i imunosupresivnih lekova. Acta Medica Medianae 2009;48(2):22-27. 
 
Ključne reči: terapija, praćenje, imunosupresivni lekovi, interakcije, presađivanje, 
bubreg 
 